 This study will investigate the effects of SRT2104 on the reduction of platelet activation markers platelet-monocyte aggregates, and to evaluate the effects of SRT2104 on platelet and monocyte surface markers P-selectin, CD11b, inflammatory markers high sensitivity CRP, IL-6, SAA, TNF-α and sCD40L, and markers of oxidative stress urinary and plasma F2-isoprostanes and nitrotyrosine. 